Loading organizations...
§ Venture Capital · Kumamoto, Japan
Holding company managing subsidiaries in healthcare and life sciences, focused on sustainable societal development.
DOJIN Capital is a Japanese venture capital firm investing in medical, biotechnology, and drug discovery sectors. It applies a focused strategy to support innovative companies within the life science and healthcare ecosystems. The firm aims to foster continuous value creation in these specialized fields by deploying strategic capital.
Established in 2015 in Kumamoto, Japan, DOJIN Capital originated from the Dojin Group, a collective with a deep history in life science innovation since 1913. The firm was founded with the insight to leverage the group's extensive scientific and medical expertise and network. Keima Ueno, CEO of Dojin Group, guides the overarching strategy.
DOJIN Capital primarily partners with venture and small to medium-sized enterprises (SMEs) in life science and healthcare, providing capital and strategic guidance. Its vision is to advance global health by empowering transformative technologies and fostering companies that develop vital solutions for human well-being. The firm aims to shape the future of medicine and biotechnology.
DOJIN Capital has 1 tracked investment across 1 company. The latest tracked deal is $2.0M Series A in Curreio in March 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 22, 2023 | Curreio | $2.0M Series A | — | 3S Capital, Asahi Kasei Pharma, Takehiko Sawabe, Ikerunippon Capital Partners, ONO Venture Investment, Kamada, U Tokyo Entrepreneur Supporter |